A study of 24,000 breast cancer survivors in Japan showed the women had significantly higher risk of non-cancer diseases -- ...

Using advanced imaging technologies as a means to enhance diagnostic accuracy was also of interest. Many HCPs pointed to the ...

The phase 3 trial enrolled 1033 patients who had not received prior chemotherapy for mCRPC and had evidence of disease progression despite androgen deprivation therapy.

A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some ...

AstraZeneca is discontinuing the CAPItello-280 Phase III trial evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared ...

The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17 ...

AZ has already thrown down a marker for its tougher stance on Europe, with an earlier decision to abandon a $560 million ...

AstraZeneca has discontinued a Phase III trial of Truqap (capivasertib) after a review concluded that the study was unlikely ...

AstraZeneca has announced the discontinuation of the CAPItello-280 Phase III trial evaluating the efficacy and safety of ...

AstraZeneca to discontinue CAPItello-280 phase III trial of Truqap in metastatic castration-resistant prostate cancer: Cambridge, UK Wednesday, April 30, 2025, 10:00 Hrs [IST] Ast ...

AstraZeneca stock rose moderately Tuesday despite a mixed first-quarter report and a setback for its experimental prostate cancer treatment.

AstraZeneca Plc’s Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage pharmaceuticals and that drugmakers are calling for no additional US levies on ...